CAS: 29578-83-4; 1-Bromo-3-Methoxy-5-Methylbenzene

上下游产品

CAS号348169-39-1 4-溴-2-甲氧基-6-甲基苯胺 | CAS号74204-00-5 3-溴-5-甲基苯酚 | CAS号74-88-4 碘甲烷 | CAS号74137-36-3 3,5-二溴苯甲醚 | CAS号77-78-1 硫酸二甲酯 | CAS号50868-73-0 2-甲氧基-6-甲基苯胺 | CAS号58169-99-6 2,3,4,6-Tetrabr... | CAS号108-39-4 间甲酚 | CAS号82477-66-5 1-氯-3-甲氧基-5-甲基苯 | CAS号3209-13-0 3-甲氧基-5-甲基苯酚 | CAS号5367-32-8 3-甲基-4-硝基苯甲醚 | CAS号38512-82-2 5-甲基-2-硝基苯甲醚 | CAS号262450-64-6 (3-溴-5-甲氧基苯基)甲醇 | CAS号874-63-5 3,5-二甲基苯甲醚 | CAS号31601-41-9 2-乙酰氨基-5-甲氧基甲苯 | CAS号74204-00-5 3-溴-5-甲基苯酚 | CAS号5345-42-6 3-甲基-2-硝基苯甲醚 | CAS号157893-14-6 3-溴-5-甲氧基苯甲酸 | CAS号262450-65-7 3-溴-5-甲氧基苯甲醛

2-甲氧基-6-甲基苯胺置于盐酸,溴,溶剂黄146,Sodium Nitrite体系中,用 甲醇 用作溶剂,化学反应 10.5H,反应生成1-溴-3-甲氧基-5-甲苯
参考文献:2-氨基-6-芳基磺酰基苯甲腈作为hiv-1的非核苷类逆转录酶抑制剂.
标题:2-氨基-6-芳基磺酰基苯甲腈作为hiv-1的非核苷类逆转录酶抑制剂.
摘要:发现一系列2-氨基-5-芳基硫代苄腈(1)具有抗hiv-1的活性.结构上的改变产生了亚砜(2)和砜(3).亚砜通常显示出与hiv-1相似的抗病毒活性.然而,砜是最有效的类似物系列,其中一些具有在纳摩尔范围内的抗hiv-1活性.结构活性关系(sar)研究表明,间位取代基,特别是间位甲基取代基,总是会增加抗病毒活性.然而,最佳的抗病毒活性由芳基磺酰基部分中的两个间位基团都被取代且取代基之一是甲基的化合物表现出来.这种混乱导致化合物3V,3W,3X和3Y在低纳摩尔范围内具有针对hiv-1的ic50值.当评估它们对关键的非核苷类逆转录酶抑制剂(nnrti)相关突变体的广谱抗病毒活性时,所有二元取代的砜3U-Z和2-萘基类似物3Ee通常显示出对数显性的单摩尔纳米摩尔活性. V106A和p236L菌株以及针对菌株e138K,V108I和y188C的亚微摩尔至低纳摩尔活性.然而,他们显示出缺乏针对k10
Doi:10.1021/jm0004906

专利信息

专利号:US-12150934-B2
优先权日:2016-11-30
标 题 :Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
发明人：SIDDIQUI ARSHAD M; CIBLAT STEPHANE; CONSTANTINEAU-FORGET LEA; GRAND-MAITRE CHANTAL; GUO XIANGYU; SRIVASTAVA SANJAY; SHIPPS GERALD W; COOPER ALAN B; OZA VIBHA; KOSTURA MATTHEW W; LUTHER MICHAEL; LEVINE JEDD
权利人:BANTAM PHARMACEUTICAL LLC
摘要:Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by “aâ€?, R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

专利号:US-10112955-B2
优先权日:2015-10-29
标题 :Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
发明人：SPRENGELER PAUL A; REICH SIEGFRIED H; ERNST JUSTIN T; WEBBER STEPHEN E; SHAGHAFI MIKE; MURPHY DOUGLAS; TRAN CHINH
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n nFor Formula I compounds A 1 , A 2 , A 3 , A 4 , A 5 , W 1 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b , and R 10 and subscript “nâ€? are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

专利号:EP-1534680-B1
优先权日:2002-08-14
标 题:Prenylation inhibitors and methods of their synthesis and use